# Patient-Derived Organoid-on-a-Chip Model for Personalized Prediction of Chemotherapy Efficacy in Pancreatic Cancer

> **NCT07683845** · — · RECRUITING · sponsor: **Beijing Daxiang Biotech Co., Ltd** · enrollment: 164 (estimated)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma (PDAC)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07683845
- **Lead sponsor:** Beijing Daxiang Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-20
- **Primary completion:** 2028-02-20
- **Final completion:** 2028-02-20
- **Target enrollment:** 164 (ESTIMATED)
- **Last updated:** 2026-07-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07683845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07683845, "Patient-Derived Organoid-on-a-Chip Model for Personalized Prediction of Chemotherapy Efficacy in Pancreatic Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07683845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*